Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02)

► Safety and immunogenicity of HIV/AIDS MVA-B. ► This first phase I trial with candidate MVA-B in healthy volunteers showed that this immunogen was safe and well tolerated. ► This vaccine elicited strong and durable T-cell responses in 75% of volunteers. ► This vaccine elicited antibody responses against HIV-1 Env in 95% of volunteers and 33% generated neutralizing antibodies ► These data support further exploration of MVA-B as an HIV-1 vaccine candidate.